Qube Research & Technologies LTD Eagle Pharmaceuticals, Inc. Transaction History
Qube Research & Technologies LTD
- $62.3 Billion
- Q2 2024
A detailed history of Qube Research & Technologies LTD transactions in Eagle Pharmaceuticals, Inc. stock. As of the latest transaction made, Qube Research & Technologies LTD holds 16,763 shares of EGRX stock, worth $71,578. This represents 0.0% of its overall portfolio holdings.
Number of Shares
16,763
Previous 3,551
372.06%
Holding current value
$71,578
Previous $18,000
416.67%
% of portfolio
0.0%
Previous 0.0%
Shares
14 transactions
Others Institutions Holding EGRX
# of Institutions
79Shares Held
9.89MCall Options Held
1.01MPut Options Held
0-
Nantahala Capital Management, LLC New Canaan, CT1.96MShares$8.38 Million0.73% of portfolio
-
Aigh Capital Management LLC Baltimore, MD1.21MShares$5.17 Million2.46% of portfolio
-
Citigroup Inc1MShares$4.28 Million0.0% of portfolio
-
Aqr Capital Management LLC Greenwich, CT697KShares$2.98 Million0.01% of portfolio
-
Vanguard Group Inc Valley Forge, PA564KShares$2.41 Million0.0% of portfolio
About EAGLE PHARMACEUTICALS, INC.
- Ticker EGRX
- Exchange NASDAQ
- Sector Healthcare
- Industry Drug Manufacturers—Specialty & Generic
- Shares Outstandng 13,015,900
- Market Cap $55.6M
- Description
- Eagle Pharmaceuticals, Inc., a pharmaceutical company, focuses on developing and commercializing product candidates to treat diseases of the central nervous system or metabolic critical care, and oncology in the United States. The company offers Ryanodex for malignant hyperthermia; and Belrapzo and Bendeka for chronic lymphocytic leukemia and in...